Physician profile
Doloris D Hawk
NPI 1508009077
$10,994.32
in general payments reported to CMS, 2019-2025
40 companies · $3,246 in 2025
The $3,246 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $1,900 · 2023: $2,416 · 2024: $3,112 · 2025: $3,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,673 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,672.84 |
| Education | $101.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,569.42 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,045.47 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $571.59 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $544.46 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Ferring Pharmaceuticals INC. | $450.35 | 2022-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $423.12 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $397.31 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Celgene Corporation | $394.29 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $387.44 | 2022-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $386.05 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $345.14 | 2022-2025 | Ibsrela |
| Pfizer INC. | $303.91 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $297.17 | 2024-2025 | Zenpep |
| Enterra Medical, INC. | $181.35 | 2025 | |
| Lilly USA, LLC | $143.83 | 2024-2025 | Omvoh |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $134.51 | 2022-2023 | Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $124.30 | 2023-2024 | Idacio |
| Evoke Pharma, INC. | $120.17 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $107.45 | 2022-2023 | Linzess |
| Blueprint Medicines Corporation | $105.41 | 2023 | |
| Braintree Laboratories, INC. | $93.32 | 2022-2024 | Suflave, Sutab |
| E.R. Squibb & Sons, L.L.C. | $90.25 | 2022 | |
| Nestle Healthcare Nutrition INC. | $85.34 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.19 | 2023-2024 | Cyltezo |
| Daiichi Sankyo INC. | $74.67 | 2022-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $70.27 | 2022-2024 | Dificid |
| Genzyme Corporation | $66.46 | 2022-2025 | |
| Madrigal Pharmaceuticals | $57.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Vivus LLC | $46.03 | 2022-2024 | Pancreaze |
| Alfasigma USA, INC. | $39.46 | 2022 | |
| Ucb, INC. | $37.70 | 2024-2025 | Bimzelx, Cimzia |
| Sandoz INC. | $34.66 | 2023-2025 | Hyrimoz |
| Exact Sciences Corporation | $31.44 | 2023 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $31.12 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $30.05 | 2024 | |
| Intra-Sana Laboratories | $25.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.94 | 2025 | Givlaari |
| Novo Nordisk INC | $18.63 | 2025 | Wegovy |
| Redhill Biopharma INC. | $14.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doloris Hawk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.